Trial Profile
A retrospective study assessing efficacy and safety of Pembrolizumab in patients with recurrent or advanced prostate cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Mar 2018
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Mar 2018 New trial record
- 10 Feb 2018 Results presented at the 2018 Genitourinary Cancers Symposium